Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6869326 | 0.86 | ADORA2A (0.76) | ADORA2AADORA2BKDM4EALOX15HSD17B10 | |
| SCHEMBL25437252 | 0.86 | ADORA2A (0.79) | ADORA2AADORA2BKDM4EALOX15HSD17B10 | |
| SCHEMBL10588368 | 0.85 | ADORA2A (1.00) | ADORA2AADORA2BKDM4EALOX15HSD17B10 | |
| SCHEMBL9762945 | 0.85 | ADORA2A (1.00) | ADORA2AADORA2BKDM4EALOX15HSD17B10 | |
| Hydrochloric Acid SCHEMBL9762842 | 0.84 | ADORA2A (0.98) | ADORA2AADORA2BKDM4EALOX15HSD17B10 | |
| SCHEMBL1081737 | 0.82 | ADORA2A (0.68) | ADORA2AADORA2BKDM4EALOX15HSD17B10 | |
| Hydrochloric Acid SCHEMBL6754869 | 0.82 | ADORA2A (0.68) | ADORA2AADORA2BKDM4EALOX15HSD17B10 | |
| SCHEMBL12102216 | 0.81 | ADORA2A (0.82) | ADORA2AADORA2BKDM4EALOX15HSD17B10 | |
| Hydrochloric Acid SCHEMBL2031971 | 0.81 | ADORA2A (0.67) | ADORA2AADORA2BKDM4EALOX15HSD17B10 | |
| SCHEMBL18124243 | 0.81 | ADORA2A (0.74) | ADORA2AADORA2BKDM4EALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247798-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA KIRIN CO LTD (JP) | 2020-08-06 | — | — | US | disclosed |
| EP-2474544-B1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-07-12 | — | — | EP | disclosed |
| EP-2474543-B1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-05-03 | — | — | EP | disclosed |
| US-9249135-B2 | Therapeutic agent for mood disorders | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20150080415-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA KIRIN CO., LTD. (JP) | 2015-03-19 | — | — | US | disclosed |
| US-20120184554-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| EP-2474544-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| EP-2474543-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120172362-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | disclosed |
| US-6040296-A | Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation | EAST CAROLINA UNIVERSITY (US) | 2000-03-21 | — | — | US | disclosed |
| WO-1999063938-A9 | COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF CARDIOPULMONARY AND RENAL FAILURE OR DAMAGE ASSOCIATED WITH ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR BROUGHT ABOUT BY ADMINISTRATION OF CERTAIN DRUGS | EPIGENESIS PHARMACEUTICALS INC (US) | 2000-03-02 | — | — | WO | disclosed |
| US-6025339-A | OLIGO IS ANTISENSE TO THE INITIATION CODON, THE CODING REGION OR THE 5' AND 3' INTRONEXON JUNCTIONS OF A GENE ENCODING THE ADENOSINE A.SUB.1 RECEPTOR OR ANTISENSE TO AN ADENOSINE A.SUB.1 RECEPTOR MRNA; AND | EAST CAROLINA UNIVERSITY (US) | 2000-02-15 | — | — | US | disclosed |
| US-5994315-A | OLIGONUCLEOTIDE IN AEROSOL FORM | EAST CAROLINA UNIVERSITY (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0946201-A1 | AGENT AND METHOD OF TREATMENT FOR DISEASES AND CONDITIONS ASSOCIATED WITH RESPIRATORY AILMENTS AND LUNG INFLAMMATION | EAST CAROLINA UNIVERSITY (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999013886-A1 | MULTIPLE TARGET HYBRIDIZING NUCLEIC ACIDS, THEIR PREPARATION, COMPOSITIONS, FORMULATION, KITS AND APPLICATIONS | EAST CAROLINA UNIVERSITY (US) | 1999-03-25 | — | — | WO | disclosed |
| WO-1998023294-A9 | AGENT AND METHOD OF TREATMENT FOR DISEASES AND CONDITIONS ASSOCIATED WITH RESPIRATORY AILMENTS AND LUNG INFLAMMATION | — | 1998-09-17 | — | — | WO | disclosed |
| WO-1998023294-A1 | AGENT AND METHOD OF TREATMENT FOR DISEASES AND CONDITIONS ASSOCIATED WITH RESPIRATORY AILMENTS AND LUNG INFLAMMATION | EAST CAROLINA UNIVERSITY (US) | 1998-06-04 | — | — | WO | disclosed |
| EP-0831924-A1 | METHOD OF TREATMENT FOR ASTHMA | EAST CAROLINA UNIVERSITY (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040266-A1 | METHOD OF TREATMENT FOR ASTHMA | EAST CAROLINA UNIVERSITY (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184554-A1 | THERAPEUTIC AGENT FOR MOOD DISORDERS | TPH1, HDAC1, HDAC2 | ADORA2A 709/4885ADORA2B 1430/4885KDM4E 2195/4885 |
| US-20120172362-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | TAAR1, SLC6A1, GABBR1 | ADORA2A 82/4885ADORA2B 193/4885KDM4E 3799/4885 |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | RECQL, GSS, DDX17 | ADORA2A 10/4885ADORA2B 15/4885KDM4E 4247/4885 |
| US-20200247798-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | TAAR1, SLC6A1, GABBR1 | ADORA2A 82/4885ADORA2B 193/4885KDM4E 3799/4885 |
| US-20150080415-A1 | THERAPEUTIC AGENT FOR ANXIETY DISORDERS | TAAR1, SLC6A1, GABBR1 | ADORA2A 82/4885ADORA2B 193/4885KDM4E 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.